1. HBW Insight
  2. >>Beauty
  3. >>Policy & Regulation
  4. >>Legislation

‘Something’s Going To Happen’: Former FDAer John Bailey On Cosmetics Reform Legislation

 
• By Ryan Nelson

ICMAD leadership agrees with Bailey that, now more than ever before, the pieces are in place for cosmetics reform legislation to reach the finish line. At the same time, the small-business advocate remains opposed to leading proposals, signaling the significant distance that negotiations may still have to go.

RS1805_Are You Ready_236374741_1200.jpg

There was a sense of unprecedented urgency and anticipation May 17 at the Independent Cosmetic Manufacturers and Distributors’ FDA regulations workshop in New York, where attendees were put on notice about changes to the oversight framework that may be on the way.

Former FDA Cosmetics Director John Bailey, who serves ICMAD in a consulting capacity now, led off the day’s presentations, advising...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legislation

Senate HELP Committee Adds Sunscreen Regulation Overhaul To OMUFA Reauthorization

 
• By Lauren Nardella

OMUFA reauthorization bill including amendment with sunscreen regulation provisions passed by Senate committee, which also approved other provisions not included in House OMUFA bill.

Sunscreen Regulation Reforms Still Could Hitch Ride On Senate OMUFA Reauthorization Bill

As stakeholders and lawmakers pin their hopes on OMUFA reauthorization as a vehicle for enacting sunscreen regulatory changes, Senate version of the bill could be the ticket after a sunscreen-specific amendment withdrawn in the House.

Unanimous Support Across House Energy And Commerce To Reauthorize FDA’s OMUFA Program

 
• By Malcolm Spicer

Committee voted 51-0 to approve five-year authorization of FDA program user fee program needed to support regulatory pathway for large majority of nonprescription drugs available in the US with amendment to expand stakeholder engagement with FDA.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

More from Policy & Regulation

US Tariff Exemption For Indonesian Materials Not Produced Domestically A Boon For Fragrance – FCA

 
• By Eileen Francis

The Fragrance Creators Association President & CEO Farah Ahmed commends the Trump Administration for exempting from tariffs Indonesian goods not naturally available or produced in the US, which recognizes the “essential” role of fragrance and essential oils.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By David Ridley

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 
• By Sarah Karlin-Smith

FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.